Navigation Links
UK Must Maintain its Momentum in Stem Cell Expertise
Date:1/19/2009

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology.

Professor Sir Christopher Evans, founder and chairman of Excalibur, welcomed the announcement that ReNeuron plc has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke.

Sir Christopher said: "We founded ReNeuron with Dr John Sinden and have invested in the company every step of the way for the last 10 years. We are proud the company has now reached this important milestone in its development of cell therapy treatment for stroke. There have been many scientific and financial hurdles to overcome during these years but we were determined to see this through.

"It is absolutely essential that we in the UK maintain our momentum in stem cell development and our belief in our ability to deliver these potentially revolutionary treatments. Too often in this country there is a tendency to focus on potentially negative outcomes but today's announcement is extremely important news for victims of stroke. At the end of the day lives - and the future of medicine in this area -- could be transformed by this science."

NOTES TO EDITORS

About Excalibur

Excalibur was launched in April 2008 following the acquisition of MVIL by Merlin Biosciences. Excalibur, which has a team of ten professionals, provides a wide range of investment and advisory services to the medical sciences sector. Its latest fund, Merlin Fund III, has successfully invested in a wide range of healthcare and medical sciences companies including PIramed which was sold for $185m in May 2008. Excalibur intends to replicate this successful investment strategy in the new funds that it is proposing to launch over the next 12 months.

Merlin originally founded ReNeuron in 1998 and has provided funding for the company over the last 10 years through Merlin 's Fund l and ll and has continued to invest in and support the company.

Further information: Ramsay Smith, Media House, +44(0)207-397-8459, Email:ramsay@mediahouse.co.uk, mobile +44(0)7788-414856.


'/>"/>
SOURCE Excalibur
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
2. Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium
3. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
4. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
7. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/25/2017)... Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is ... the treatment of acute or chronic problems, I focus on preventative care with all my ... If you have any questions, always feel free to contact my office and my trained ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... TN (PRWEB) , ... April 24, 2017 , ... Michael ... fans and transforming the quarterback position. The former overall number one pick in the ... professional football career. He holds the record for the most career rushing yards by ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... Educational Research Association’s Outstanding Public Communication of Education Research Award. The award honors ... including education communities. It recognizes a scholar who has demonstrated the capacity to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed king of ... Juiceman Juicer, and the George Foreman Grill (which sold more than 100 million units ... last 25 years. , Now, due to changes in the broadcast media landscape, the ...
Breaking Medicine News(10 mins):